aojtha9p

Property	Value
?:abstract	OBJECTIVE: Single cases and small series of Guillain-Barré syndrome (GBS) have been reported during the SARS-CoV-2 outbreak worldwide. We evaluated incidence and clinical features of GBS in a cohort of patients from two regions of northern Italy with the highest number of patients with COVID-19. METHODS: GBS cases diagnosed in 12 referral hospitals from Lombardy and Veneto in March and April 2020 were retrospectively collected. As a control population, GBS diagnosed in March and April 2019 in the same hospitals were considered. RESULTS: Incidence of GBS in March and April 2020 was 0.202/100 000/month (estimated rate 2.43/100 000/year) vs 0.077/100 000/month (estimated rate 0.93/100 000/year) in the same months of 2019 with a 2.6-fold increase. Estimated incidence of GBS in COVID-19-positive patients was 47.9/100 000 and in the COVID-19-positive hospitalised patients was 236/100 000. COVID-19-positive patients with GBS, when compared with COVID-19-negative subjects, showed lower MRC sum score (26.3±18.3 vs 41.4±14.8, p=0.006), higher frequency of demyelinating subtype (76.6% vs 35.3%, p=0.011), more frequent low blood pressure (50% vs 11.8%, p=0.017) and higher rate of admission to intensive care unit (66.6% vs 17.6%, p=0.002). CONCLUSIONS: This study shows an increased incidence of GBS during the COVID-19 outbreak in northern Italy, supporting a pathogenic link. COVID-19-associated GBS is predominantly demyelinating and seems to be more severe than non-COVID-19 GBS, although it is likely that in some patients the systemic impairment due to COVID-19 might have contributed to the severity of the whole clinical picture.
is ?:annotates of	<https://research.tib.eu/covid-19/entity/aojtha9p_hasAnnotation_C1540289> <https://research.tib.eu/covid-19/entity/aojtha9p_hasAnnotation_C5203676>
?:creator	<https://research.tib.eu/covid-19/entity/Filosto%2C_Massimiliano%3B_Cotti_Piccinelli%2C_Stefano%3B_Gazzina%2C_Stefano%3B_Foresti%2C_Camillo%3B_Frigeni%2C_Barbara%3B_Servalli%2C_Maria_Cristina%3B_Sessa%2C_Maria%3B_Cosentino%2C_Giuseppe%3B_Marchioni%2C_Enrico%3B_Ravaglia%2C_Sabrina%3B_Briani%2C_Chiara%3B_Castellani%2C_Francesca%3B_Zara%2C_Gabriella%3B_Bianchi%2C_Francesca%3B_Del_Carro%2C_Ubaldo%3B_Fazio%2C_Raffaella%3B_Filippi%2C_Massimo%3B_Magni%2C_Eugenio%3B_Natalini%2C_Giuseppe%3B_Palmerini%2C_Francesco%3B_Perotti%2C_Anna_Maria%3B_Bellomo%2C_Andrea%3B_Osio%2C_Maurizio%3B_Scopelliti%2C_Giuseppe%3B_Carpo%2C_Marinella%3B_Rasera%2C_Andrea%3B_Squintani%2C_Giovanna%3B_Doneddu%2C_Pietro_Emiliano%3B_Bertasi%2C_Valeria%3B_Cotelli%2C_Maria_Sofia%3B_Bertolasi%2C_Laura%3B_Fabrizi%2C_Gian_Maria%3B_Ferrari%2C_Sergio%3B_Ranieri%2C_Federico%3B_Caprioli%2C_Francesca%3B_Grappa%2C_Elena%3B_Broglio%2C_Laura%3B_De_Maria%2C_Giovanni%3B_Leggio%2C_Ugo%3B_Poli%2C_Loris%3B_Rasulo%2C_Frank%3B_Latronico%2C_Nicola%3B_Nobile-Orazio%2C_Eduardo%3B_Padovani%2C_Alessandro%3B_Uncini%2C_Antonino>
?:doi	10.1136/jnnp-2020-324837
?:doi	<https://research.tib.eu/covid-19/entity/10.1136/jnnp-2020-324837>
?:journal	J_Neurol_Neurosurg_Psychiatry
?:license	no-cc
?:pdf_json_files	document_parses/pdf_json/efb6b842a141431c90a68e86c86c9f67b9394a32.json
?:pmc_json_files	document_parses/pmc_json/PMC7650204.xml.json
?:pmcid	<https://research.tib.eu/covid-19/entity/PMC7650204>
?:pmid	<https://research.tib.eu/covid-19/entity/33158914.0>
?:pmid	33158914.0
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
is ?:relation_isRelatedTo_publication of	<https://research.tib.eu/covid-19/entity/aojtha9p_HAS_C0018378_COEXISTS_WITH_C1856053> <https://research.tib.eu/covid-19/entity/aojtha9p_HAS_C5203670_CAUSES_C0018378>
?:sha_id	<https://research.tib.eu/covid-19/entity/efb6b842a141431c90a68e86c86c9f67b9394a32>
?:source	Medline; PMC
?:title	Guillain-Barré syndrome and COVID-19: an observational multicentre study from two Italian hotspot regions
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:year	2020-11-06

Property

Value

?:abstract

OBJECTIVE: Single cases and small series of Guillain-Barré syndrome (GBS) have been reported during the SARS-CoV-2 outbreak worldwide. We evaluated incidence and clinical features of GBS in a cohort of patients from two regions of northern Italy with the highest number of patients with COVID-19. METHODS: GBS cases diagnosed in 12 referral hospitals from Lombardy and Veneto in March and April 2020 were retrospectively collected. As a control population, GBS diagnosed in March and April 2019 in the same hospitals were considered. RESULTS: Incidence of GBS in March and April 2020 was 0.202/100 000/month (estimated rate 2.43/100 000/year) vs 0.077/100 000/month (estimated rate 0.93/100 000/year) in the same months of 2019 with a 2.6-fold increase. Estimated incidence of GBS in COVID-19-positive patients was 47.9/100 000 and in the COVID-19-positive hospitalised patients was 236/100 000. COVID-19-positive patients with GBS, when compared with COVID-19-negative subjects, showed lower MRC sum score (26.3±18.3 vs 41.4±14.8, p=0.006), higher frequency of demyelinating subtype (76.6% vs 35.3%, p=0.011), more frequent low blood pressure (50% vs 11.8%, p=0.017) and higher rate of admission to intensive care unit (66.6% vs 17.6%, p=0.002). CONCLUSIONS: This study shows an increased incidence of GBS during the COVID-19 outbreak in northern Italy, supporting a pathogenic link. COVID-19-associated GBS is predominantly demyelinating and seems to be more severe than non-COVID-19 GBS, although it is likely that in some patients the systemic impairment due to COVID-19 might have contributed to the severity of the whole clinical picture.

is ?:annotates of